CSG's 58% Rout: How a Billion-Euro Valuation Gap and a Shrinking Coalition Overrode Record Profits

Valuation dispute between CSG's majority and minority owners sinks stock 58% despite record orders, strong earnings, and new US Army deal.

A bitter boardroom battle playing out across Czech and Slovak courts has become the single biggest drag on Czechoslovak Group's share price, drowning out a record €17 billion order book and an 83% surge in quarterly earnings. The stock closed Friday at €15.05, a staggering 58% below its January high of €36.05 and down nearly 17% in just the past seven days. The sell-off has been so relentless that the 52-week low of €13.65, touched in May, now sits only 10% below the current level.

The heart of the dispute is a massive valuation gap between majority owner Michal Strnad and minority shareholder Petr Kratochvíl. Kratochvíl, who holds about 10% of CSG Land Systems CZ and roughly 9% of MSM Group, is demanding some 35 billion Czech crowns for his stakes. Strnad’s counter-offer stands at just 4 billion crowns — a chasm of 31 billion that has frozen all negotiations. Kratochvíl was removed as chairman in March over conflict-of-interest concerns. Since then, he has been challenging not only the valuation of his holdings but also certain share transfers within MSM Group dating back to early 2026. For investors, each positive quarterly report lands against a backdrop of governance uncertainty that cannot be priced away.

Political winds have added another layer of pressure. The Czech-led munitions initiative for Ukraine, which once counted 18 donor countries at its peak, has shrunk to roughly nine financial backers, according to Czech President Petr Pavel in a Financial Times interview. The programme has delivered more than four million large-calibre artillery shells to Kyiv since 2024. CSG remains its primary partner for procurement and processing of shells from non-NATO sources. CEO Strnad has indicated that direct purchases by individual governments — bypassing the coordinated Czech channel — could compensate for part of the decline. Some countries are now buying artillery ammunition directly from CSG and other suppliers, softening the blow but not removing the headline risk.

On the operational front, CSG has been anything but idle. On June 1, a subsidiary signed an accelerated development and delivery deal for high-performance munitions with the US Army. A day later, CSG raised its stake in German specialty chemicals group Alzchem to over 20% through a combination of direct voting rights (9.9% via subsidiary Staluna Trade) and total-return swaps that run until May 2027. Alzchem produces nitroguanidine, a key ingredient for munitions and propellants; the stock gained 6% on the news. In Ukraine, a licensing partnership with Ukrainian Armor launched NATO-calibre artillery shell production at a target of 100,000 155-mm and 50,000 105-mm rounds per year. In Slovakia, a new line for long-range munitions with an annual capacity of 70,000 units is already running at full load. A joint venture with South Africa’s Reunert — Fuchs Electronics Europe, split 51/49 in Reunert’s favour — is producing electronic fuses.

The first quarter of 2026 offered unambiguous evidence of operational strength. Revenue rose 13.8% to €1.544 billion, operating EBIT hit €372 million for a 24.1% margin, and net profit jumped 83% to €299 million, lifting the net margin from 12% to 19%. The order book reached a record €17 billion, up from €15 billion at the end of 2025, with a pipeline of €27 billion under negotiation. CSG reaffirmed its full-year outlook: revenue between €7.4 billion and €7.6 billion, an operating EBIT margin of 24% to 25%, and a net-debt-to-EBITDA ratio below 1.3. A short-seller report from Hunterbrook Media — whose affiliated vehicle holds a disclosed short position — levelled critical allegations about the company's governance and disclosures. CSG dismissed them as misrepresentations and stood by the integrity of its prospectus and all subsequent filings.

Analysts find themselves in an awkward spot. Ten rate the stock a strong buy, with a median price target of €32.05 — more than double the current price. Berenberg recently trimmed its estimates and target, citing uneven segment results in the first quarter. Technically, the relative strength index sits at 31.8, firmly in oversold territory. Annualised volatility of roughly 77% underscores how sharply the market reacts to any CSG news. Half-year results for the period through June 30 are due on August 7, with a quiet period beginning July 8. Until then, the story remains one of stellar operations versus a market that simply will not look past the headlines.